ANNX Insider Trading

Insider Ownership Percentage: 12.67%
Insider Buying (Last 12 Months): $89,984.00
Insider Selling (Last 12 Months): $224,444.81

Annexon Insider Trading History Chart

This chart shows the insider buying and selling history at Annexon by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$5M$0$5MTotal Insider BuyingTotal Insider Selling

Annexon Share Price & Price History

Current Price: $1.79
Price Change: Price Decrease of -0.139 (-7.20%)
As of 04/1/2025 03:06 PM ET

This chart shows the closing price history over time for ANNX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$1.93Closing price on 03/31/25:

SEC Filings (Institutional Ownership Changes) for Annexon (NASDAQ:ANNX)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ANNX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$14Mbought$11MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10M$0$10MTotal InflowsTotal Outflows
Annexon logo
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Read More on Annexon

Today's Range

Now: $1.79
Low: $1.81
High: $1.99

50 Day Range

MA: $3.00
Low: $1.93
High: $4.24

52 Week Range

Now: $1.79
Low: $1.81
High: $7.85

Volume

1,257,196 shs

Average Volume

1,474,860 shs

Market Capitalization

$196.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.14

Who are the company insiders with the largest holdings of Annexon?

Annexon's top insider investors include:
  1. Muneer A Satter (Director)
  2. Bain Capital Life Sciences Inv (Major Shareholder)
  3. Douglas Love (CEO)
  4. Michael Overdorf (EVP)
  5. Jennifer Lew (CFO)
  6. Dean Richard Artis (EVP)
  7. Ted Yednock (EVP)
  8. Jamie Dananberg (Insider)
  9. William H Carson (Director)
Learn More about top insider investors at Annexon.